How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation

AIMS: Since 2008, KRAS mutation status in exon 2 has been used to predict response to anti-EGFR therapies. Recent evidence has demonstrated that NRAS status is also predictive of response. Several retrospective ‘extended RAS’ analyses have been performed on clinical trial material. Despite this, are...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Pathol
Asıl Yazarlar: Richman, Susan D, Fairley, Jennifer, Butler, Rachel, Deans, Zandra C
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2017
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5256378/
https://ncbi.nlm.nih.gov/pubmed/27681846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jclinpath-2016-203822
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller